Coumarin-pyrazoline hybrids as selective inhibitors of the tumor-associated carbonic anhydrase IX and XII

Aim: Human carbonic anhydrase (CA, EC 4.2.1.1) isoforms IX and XII are validated antitumor/antimetastatic drug and tumor imaging targets with sulfonamide inhibitors and monoclonal antibodies in clinical development. Coumarins act as isoform-selective inhibitors of these isoforms over the cytosolic and mitochondrial ones. Materials and methods: We report the synthesis and in vitro CA inhibitory evaluation of a large panel of coumarins incorporating pyrazole-1-carboxamide moieties. Compounds were fully characterized before the assessment of their inhibitory activity. A stopped-flow CO2 hydrase assay was performed for the biological test. Results: These coumarins did not inhibit the widespread, off-target isoforms CA I and II (KI 50 μM), but they were sub-micromolar CA IX/XII inhibitors with an interesting selectivity index higher than the reference compound. Selectivity between α- and β-class of CAs was also promising. Conclusion: These compounds may be used as leads for the rational design and development of non-sulfonamide CA IX/XII effective inhibitors.